407 related articles for article (PubMed ID: 29336889)
21. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
[TBL] [Abstract][Full Text] [Related]
22. Dimerization Is Critical for the Functions of Wild-type and Mutant KRAS.
Cancer Discov; 2018 Mar; 8(3):262. PubMed ID: 29374019
[TBL] [Abstract][Full Text] [Related]
23. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
24. D154Q Mutation does not Alter KRAS Dimerization.
Grozavu I; Stuart S; Lyakisheva A; Yao Z; Pathmanathan S; Ohh M; Stagljar I
J Mol Biol; 2022 Jan; 434(2):167392. PubMed ID: 34896362
[TBL] [Abstract][Full Text] [Related]
25. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
26. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
[TBL] [Abstract][Full Text] [Related]
27. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
[TBL] [Abstract][Full Text] [Related]
28.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
29. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
Drosten M; Barbacid M
Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
[TBL] [Abstract][Full Text] [Related]
30. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
31. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
Elife; 2018 Nov; 7():. PubMed ID: 30475204
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
33. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
Yen I; Shanahan F; Merchant M; Orr C; Hunsaker T; Durk M; La H; Zhang X; Martin SE; Lin E; Chan J; Yu Y; Amin D; Neve RM; Gustafson A; Venkatanarayan A; Foster SA; Rudolph J; Klijn C; Malek S
Cancer Cell; 2018 Oct; 34(4):611-625.e7. PubMed ID: 30300582
[TBL] [Abstract][Full Text] [Related]
35. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
36. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
37. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
38. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
39. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
40. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
